Skip to main
DBD

DBD Stock Forecast & Price Target

DBD Analyst Ratings

Based on 2 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Diebold Nixdorf Inc has demonstrated a strong performance in its Retail segment, with revenues of $255 million reflecting an 8.1% increase quarter-over-quarter and a 7.8% rise year-over-year, while gross margins improved by 100 basis points to 24.7%. The company is on track to achieve significant growth in free cash flow, with projections estimating nearly double the figure for 2025 compared to 2024, indicating sustainable financial health. Additionally, robust year-over-year earnings per share growth is anticipated for 2026, supported by revenue growth and targeted margin expansions, which underscores a positive outlook for the company’s financial performance.

Bears say

Diebold Nixdorf's stock faces a negative outlook primarily due to technological missteps and an inability to innovate, which could hinder its revenue growth and profitability, particularly within its Banking segment where gross margins have recently declined. The company anticipates significant operational expense savings but may struggle to offset tariff-related costs and faces growing pricing pressure from increased competition, further complicating its financial stability. Additionally, factors such as supply chain disruptions, lower than expected demand for upgrades, and foreign exchange volatility pose substantial risks that could exacerbate the company’s challenges moving forward.

DBD has been analyzed by 2 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Diebold Nixdorf Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Diebold Nixdorf Inc (DBD) Forecast

Analysts have given DBD a Buy based on their latest research and market trends.

According to 2 analysts, DBD has a Buy consensus rating as of Feb 19, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $100, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $100, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Diebold Nixdorf Inc (DBD)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.